Home › Companies › RYTM

RHYTHM PHARMACEUTICALS, INC.

RYTM Rare disease Lead: Approved 6 Biotech Distilled articles ↓

Metabolic Peptide Small Molecule

Most recent annual filing: 2026-02-15

Pipeline (13 active programs)

IMCIVREE

setmelanotide

Peptide Target: MC4R

Bardet-Biedl Syndrome Approved subcutaneous
POMC Deficiency Obesity Approved subcutaneous
LEPR Deficiency Obesity Approved subcutaneous
Acquired Hypothalamic Obesity NDA Submitted subcutaneous
Congenital Hypothalamic Obesity Phase 3 subcutaneous
Prader-Willi Syndrome Phase 2 subcutaneous
POMC Insufficiency Obesity Phase 3 subcutaneous
LEPR Insufficiency Obesity Phase 3 subcutaneous
SRC1 Deficiency Obesity Phase 3 subcutaneous
SH2B1 Deficiency Obesity Phase 3 subcutaneous

bivamelagon

LB54640

Small Molecule Target: MC4R

Acquired Hypothalamic Obesity Phase 3 oral

RM-718

Peptide Target: MC4R

Acquired Hypothalamic Obesity Phase 1 subcutaneous
Prader-Willi Syndrome Phase 1 subcutaneous

Biotech Distilled coverage (6)

2026-05-06 UPDATE: Rhythm Pharmaceuticals (RYTM) - The Launch Metric That Flipped the Script 🔒 Paid
2026-03-29 UPDATE: Rhythm Pharmaceuticals (RYTM) - The CHMP Gives a Green Light, but the ATM Hangover Persists 🔒 Paid
2026-03-22 UPDATE: Rhythm Therapeutics (RYTM) - The Agony, The Ecstasy, and The P-Hacking Reality Check 🔒 Paid
2026-03-07 UPDATE: Rhythm Therapeutics (RYTM) - Final TRANSCEND Data Drop Cements the HO Thesis Ahead of PDUFA 🔒 Paid
2026-02-28 RYTM Update: Dissecting the Earnings, the Oral Pipeline, and the Wall of Paper 🔒 Paid
2026-01-19 Rhythm Therapeutics (RYTM): Scientific Deep Dive for Setmelanotide and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.